Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15946) 15946
Book Review (1968) 1968
Publication (1105) 1105
Newsletter (132) 132
Conference Proceeding (40) 40
Book Chapter (33) 33
Book / eBook (10) 10
Magazine Article (10) 10
Dissertation (9) 9
Newspaper Article (9) 9
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14607) 14607
humans (9549) 9549
animals (7622) 7622
female (6534) 6534
male (5984) 5984
mice (5636) 5636
immunology (4700) 4700
interleukin-2 (4357) 4357
middle aged (3460) 3460
adult (3373) 3373
oncology (3318) 3318
immunotherapy (3126) 3126
interleukin-2 - administration & dosage (2808) 2808
aged (2387) 2387
interleukin-2 - therapeutic use (2238) 2238
cancer (1980) 1980
mice, inbred c57bl (1843) 1843
mice, inbred balb c (1747) 1747
lymphocytes (1725) 1725
cytokines (1724) 1724
abridged index medicus (1721) 1721
t-lymphocytes - immunology (1720) 1720
interleukin-2 - pharmacology (1648) 1648
expression (1457) 1457
interleukin-2 - biosynthesis (1415) 1415
t cells (1409) 1409
medicine, research & experimental (1338) 1338
cells, cultured (1333) 1333
interleukin-2 - immunology (1287) 1287
rats (1265) 1265
therapy (1229) 1229
lymphocyte activation (1219) 1219
treatment outcome (1213) 1213
interleukin-2 - metabolism (1206) 1206
pharmacology & pharmacy (1157) 1157
t-lymphocytes, regulatory - immunology (1125) 1125
killer cells, natural - immunology (1117) 1117
recombinant interleukin-2 (1100) 1100
in-vivo (1053) 1053
cd4-positive t-lymphocytes - immunology (1030) 1030
interleukin-2 - adverse effects (998) 998
flow cytometry (997) 997
t-cells (981) 981
il-2 (955) 955
melanoma (938) 938
antineoplastic combined chemotherapy protocols - therapeutic use (930) 930
dendritic cells (925) 925
lymphocyte activation - drug effects (923) 923
transplantation (917) 917
interleukin-2 - genetics (899) 899
time factors (899) 899
care and treatment (896) 896
activation (893) 893
cells (886) 886
research (872) 872
cell biology (858) 858
health aspects (855) 855
dose-response relationship, drug (852) 852
hematology (829) 829
combined modality therapy (824) 824
surgery (814) 814
induction (754) 754
interleukin 2 (731) 731
analysis (719) 719
spleen - immunology (711) 711
adolescent (710) 710
t-lymphocytes - drug effects (708) 708
disease models, animal (700) 700
interferon-gamma - biosynthesis (671) 671
antineoplastic agents - therapeutic use (665) 665
biochemistry & molecular biology (654) 654
cd8-positive t-lymphocytes - immunology (651) 651
antigens (648) 648
regulatory t-cells (647) 647
recombinant proteins - administration & dosage (646) 646
interleukins (640) 640
drug administration schedule (639) 639
spleen - cytology (628) 628
interleukin-2 - blood (624) 624
interferon-gamma (623) 623
neoplasms - therapy (622) 622
article (614) 614
kidney neoplasms - drug therapy (612) 612
antibodies, monoclonal - therapeutic use (608) 608
metastatic melanoma (604) 604
carcinoma, renal cell - drug therapy (601) 601
recombinant proteins - therapeutic use (598) 598
chemotherapy (588) 588
immunotherapy - methods (588) 588
kidney neoplasms - therapy (576) 576
melanoma - drug therapy (574) 574
carcinoma, renal cell - therapy (566) 566
interferon (558) 558
inflammation (557) 557
melanoma - therapy (554) 554
tumors (553) 553
immunity (552) 552
t-lymphocyte subsets - immunology (549) 549
survival (547) 547
aids/hiv (546) 546
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15519) 15519
Japanese (207) 207
Chinese (116) 116
German (80) 80
Russian (67) 67
French (59) 59
Italian (26) 26
Spanish (15) 15
Polish (14) 14
Danish (4) 4
Turkish (3) 3
Dutch (2) 2
Hungarian (2) 2
Korean (2) 2
Romanian (2) 2
Czech (1) 1
Georgian (1) 1
Hebrew (1) 1
Norwegian (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text IL-2 administration increases CD4(+)CD25(hi) Foxp3(+) regulatory T cells in cancer patients
by Ahmadzadeh, M and Rosenberg, ST
BLOOD, ISSN 0006-4971, 03/2006, Volume 107, Issue 6, pp. 2409 - 2414
Interleukin-2 (IL-2) is historically known as a T-cell growth factor. Accumulating evidence from knockout mice suggests that IL-2 is crucial for the... 
INTERLEUKIN-2 | IMMUNITY | MEMORY | VIVO | TOLERANCE | TRANSCRIPTION FACTOR FOXP3 | PERIPHERAL-BLOOD | INDUCTION | HEMATOLOGY | LYMPHOCYTES | ANTIGEN | Humans | Middle Aged | Kidney Neoplasms - immunology | Male | Forkhead Transcription Factors - drug effects | Forkhead Transcription Factors - genetics | T-Lymphocytes, Regulatory - drug effects | Interleukin-2 - administration & dosage | Melanoma - immunology | Melanoma - drug therapy | Adolescent | Forkhead Transcription Factors - analysis | Interleukin-2 - pharmacology | Lymphocyte Count | Adult | Female | Kidney Neoplasms - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Safety and immunologic effects of IL-15 administration in nonhuman primates
by Berger, S. Carolina and Berger, Michael and Hackman, Robert C and Gough, Michael and Elliott, Carole and Jensen, Michael C and Riddell, Stanley R
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 12, pp. 2417 - 2426
The administration of cytokines that modulate endogenous or transferred T-cell immunity could improve current approaches to clinical immunotherapy.... 
METASTATIC MELANOMA | MEMORY | RECEPTOR-BETA-CHAIN | IMMUNE-RESPONSES | IN-VIVO | ACTIVATED KILLER-CELLS | INTERLEUKIN-2 RECEPTOR | HEMATOLOGY | CANCER | CD8(+) T-CELLS | ANTIGEN | Interleukin-2 - metabolism | T-Lymphocyte Subsets - immunology | Interleukin-15 - administration & dosage | Macaca nemestrina | Enzyme-Linked Immunosorbent Assay | Glycosylation | T-Lymphocytes, Regulatory - immunology | Animals | Flow Cytometry | CD8-Positive T-Lymphocytes - metabolism | Killer Cells, Natural - immunology | CD8-Positive T-Lymphocytes - immunology | Genes, T-Cell Receptor | Immunologic Memory - immunology | Apoptosis | Index Medicus | Abridged Index Medicus | Immunobiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma
by Federico, Sara M and McCarville, M. Beth and Shulkin, Barry L and Sondel, Paul M and Hank, Jacquelyn A and Hutson, Paul and Meagher, Michael and Shafer, Aaron and Ng, Catherine Y and Leung, Wing and Janssen, William E and Wu, Jianrong and Mao, Shenghua and Brennan, Rachel C and Santana, Victor M and Pappo, Alberto S and Furman, Wayne L
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Near-term anti-CD25 monoclonal antibody administration protects murine liver from ischemia-reperfusion injury due to reduced numbers of CD4 + T cells
by Yang, Jinghui and Wang, Xiaoyu and Song, Shaohua and Liu, Fang and Fu, Zhiren and Wang, Quanxing
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, pp. e106892 - e106892
Background: CD4(+) T cell is acknowledged as a key factor in the initiation phase of liver ischemia reperfusion injury. The purpose of current study is to... 
RESPONSES | CONTRIBUTE | RANDOMIZED-TRIALS | IMMUNOSUPPRESSION | MULTIDISCIPLINARY SCIENCES | HEPATIC ISCHEMIA/REPERFUSION | INDUCTION | KIDNEY | BASILIXIMAB | LYMPHOCYTES | TRANSPLANTATION | Liver - pathology | CD8-Positive T-Lymphocytes - pathology | Cell Proliferation | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Interleukin-6 - antagonists & inhibitors | Tumor Necrosis Factor-alpha - genetics | Male | Interleukin-2 - antagonists & inhibitors | CD4-Positive T-Lymphocytes - pathology | CD4-Positive T-Lymphocytes - immunology | Liver - immunology | Interleukin-2 - immunology | Interleukin-2 Receptor alpha Subunit - genetics | Liver - drug effects | Time Factors | Interferon-gamma - antagonists & inhibitors | Tumor Necrosis Factor-alpha - immunology | Interferon-gamma - genetics | Reperfusion Injury - genetics | Interleukin-2 Receptor alpha Subunit - immunology | Gene Expression | Interleukin-6 - genetics | Reperfusion Injury - pathology | Immunomodulation | Mice, Inbred C57BL | Immunophenotyping | CD4 Lymphocyte Count | Interleukin-2 - genetics | Animals | Reperfusion Injury - prevention & control | Antibodies, Monoclonal - administration & dosage | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Reperfusion Injury - immunology | Interleukin-6 - immunology | Mice | Primary Cell Culture | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Flow cytometry | Transplants & implants | Syngeneic grafts | CD8 antigen | Liver | Immunoglobulin G | Lymphocytes T | Interleukin 6 | Reperfusion | Allografts | Ischemia | Interleukin 2 | Lymphocytes | Rodents | CD25 antigen | Antigens | Damage assessment | Cytokines | Inflammation | Tumor necrosis factor-α | CD4 antigen | Injury prevention | Hepatocytes | γ-Interferon | Monoclonal antibodies | Interferon | Laboratory animals | Immunofluorescence | Binding sites | Liver transplantation | Kidney transplantation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group
by Jean-Marc Tourani and Christian Pfister and Nicole Tubiana and Mahmoud Ouldkaci and Gilles Prevot and Virginie Lucas and Stéphane Oudard and Maxime Malet and Paul Cottu and Jean-Marc Ferrero and Didier Mayeur and Olivier Rixe and Xu-Shan Sun and Olivier Bernard and Thierry Andre and Christophe Tournigand and Xavier Muracciole and Joelle Guilhot and Subcutaneous Administration Propeukin Program Cooperative Group
Journal of Clinical Oncology, ISSN 0732-183X, 11/2003, Volume 21, Issue 21, pp. 3987 - 3994
(Purpose) under bar: This outpatient multicenter trial tested the hypothesis that subcutaneous administration of an interleukin-2 (IL-2)/interferon alfa... 
PROGNOSTIC FACTORS | SURVIVAL | ADVANCED CANCER | THERAPY | ONCOLOGY | RECOMBINANT HUMAN INTERLEUKIN-2 | OUTPATIENT TREATMENT | ACTIVATED KILLER-CELLS | FOLLOW-UP | HIGH-DOSE INTERLEUKIN-2 | MULTIVARIATE-ANALYSIS | Blood Sedimentation | Prognosis | Interleukin-2 - adverse effects | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Interleukin-2 - administration & dosage | Injections, Subcutaneous | Adult | Female | Carcinoma, Renal Cell - drug therapy | Drug Therapy, Combination | France | Drug Administration Schedule | Treatment Outcome | Ambulatory Care | Interferon-alpha - administration & dosage | Carcinoma, Renal Cell - secondary | Survival Analysis | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
by Carsten Krieg and Sven Létourneau and Giuseppe Pantaleo and Onur Boyman and James P. Allison
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2010, Volume 107, Issue 26, pp. 11906 - 11911
IL-2 immunotherapy is an attractive treatment option for certain metastatic cancers. However, administration of IL-2 to patients can lead, by ill-defined... 
Receptors | Lungs | Cell lines | Melanoma | Cellular immunity | Mice | Natural killer cells | Pulmonary edema | Endothelial cells | Tumors | Tumor | T cell | Cytokine/mAb complexes | Cytokine | NK cell | cytokine | IMMUNE-COMPLEXES | MULTIDISCIPLINARY SCIENCES | ANTIBODY | ALPHA | TOXICITY | RENAL-CANCER | tumor | cytokine/mAb complexes | IN-VIVO | BIOLOGICAL-ACTIVITY | REGULATORY T-CELLS | HIGH-DOSE INTERLEUKIN-2 | CD8(+) CELLS | Recombinant Proteins - therapeutic use | Immunotherapy - methods | Interleukin-2 - adverse effects | Homeodomain Proteins - metabolism | Humans | Interleukin-2 - therapeutic use | Interleukin-2 - antagonists & inhibitors | Recombinant Proteins - adverse effects | Lung - cytology | Pulmonary Edema - etiology | Interleukin-2 Receptor alpha Subunit - genetics | Lymphocytes - immunology | Melanoma, Experimental - immunology | Lung Neoplasms - secondary | Interleukin-2 - administration & dosage | Melanoma, Experimental - secondary | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - deficiency | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Receptors, Interleukin-2 - metabolism | Lung Neoplasms - therapy | Homeodomain Proteins - genetics | Recombinant Proteins - administration & dosage | Immunotherapy - adverse effects | Mice, Knockout | Endothelial Cells - immunology | Lung Neoplasms - immunology | Animals | Interleukin-2 Receptor alpha Subunit - metabolism | Antibodies, Monoclonal - administration & dosage | Pulmonary Edema - immunology | Antigen-Antibody Complex - administration & dosage | Antigen-Antibody Complex - immunology | Lung - immunology | Care and treatment | Interleukin-2 | Health aspects | Immunotherapy | Methods | Immunology | Lymphocytes | Rodents | Metastasis | Cells | Cancer | Index Medicus | Biological Sciences | mAb complexes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
by Bachanova, Veronika and Cooley, Sarah and Defor, Todd E and Verneris, Michael R and Zhang, Bin and McKenna, David H and Curtsinger, Julie and Panoskaltsis-Mortari, Angela and Lewis, Dixie and Hippen, Keli and McGlave, Philip and Weisdorf, Daniel J and Blazar, Bruce R and Miller, Jeffrey S
Blood, ISSN 0006-4971, 06/2014, Volume 123, Issue 25, pp. 3855 - 3863
Haploidentical natural killer (NK) cell infusions can induce remissions in some patients with acute myeloid leukemia (AML) but regulatory T-cell (Treg)... 
THERAPY | NK CELLS | REGULATORY T-CELLS | 4-1BB | BLOCKADE | HEMATOLOGY | VIVO EXPANSION | EXPRESSION | CANCER | Diphtheria Toxin - administration & dosage | Recombinant Fusion Proteins - immunology | Cyclophosphamide - administration & dosage | Cell Proliferation | Coculture Techniques | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Child, Preschool | Male | T-Lymphocytes, Regulatory - immunology | Leukemia, Myeloid - pathology | Young Adult | Diphtheria Toxin - therapeutic use | Interleukin-2 - immunology | Interleukin-2 - administration & dosage | T-Lymphocytes, Regulatory - cytology | Killer Cells, Natural - immunology | Adult | Female | Child | Recombinant Fusion Proteins - administration & dosage | Killer Cells, Natural - transplantation | Acute Disease | Treatment Outcome | Combined Modality Therapy | Vidarabine - analogs & derivatives | Diphtheria Toxin - immunology | Antineoplastic Combined Chemotherapy Protocols - immunology | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | K562 Cells | Aged | Vidarabine - administration & dosage | Leukemia, Myeloid - therapy | Lymphocyte Depletion - methods | Index Medicus | Abridged Index Medicus | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
by Michael B. Atkins and Jessie Hsu and Sandra Lee and Gary I. Cohen and Lawrence E. Flaherty and Jeffrey A. Sosman and Vernon K. Sondak and John M. Kirkwood and Eastern Cooperative Oncology Group
Journal of Clinical Oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 35, pp. 5748 - 5754
Purpose Phase II trials with biochemotherapy (BCT) have shown encouraging response rates in metastatic melanoma, and meta-analyses and one phase III trial have... 
MAINTENANCE BIOTHERAPY | SURVIVAL | METAANALYSIS | SUBCUTANEOUS INTERLEUKIN-2 | ONCOLOGY | EUROPEAN ORGANIZATION | RANDOMIZED-TRIAL | RECOMBINANT INTERLEUKIN-2 | COMBINATION | CHEMOTHERAPY | PROGRESSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Recombinant Proteins | Young Adult | Neoplasm Metastasis | Time Factors | Interleukin-2 - administration & dosage | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Dacarbazine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Melanoma - pathology | Interferon-alpha - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Aged | Melanoma - mortality | Index Medicus | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
by Lesterhuis, W. Joost and de Vries, I. Jolanda M and Schreibelt, Gerty and Lambeck, Annechien J. A and Aarntzen, Erik H. J. G and Jacobs, Joannes F. M and Scharenborg, Nicole M and van de Rakt, Mandy W. M. M and de Boer, Annemiek J and Croockewit, Sana and van Rossum, Michelle M and Mus, Roel and Oyen, Wim J. G and Boerman, Otto C and Lucas, Sophie and Adema, Gosse J and Punt, Cornelis J. A and Figdor, Carl G
Clinical cancer research, ISSN 1078-0432, 2011, Volume 17, Issue 17, pp. 5725 - 5735
It is unknown whether the route of administration influences dendritic cell (DC)-based immunotherapy. We compared the effect of intradermal versus intranodal... 
INTERLEUKIN-2 | METASTATIC MELANOMA | CANCER-PATIENTS | THERAPY | ONCOLOGY | IMMUNOTHERAPY | PHASE-I/II | LYMPH-NODES | TUMOR-MESSENGER-RNA | PERIPHERAL-BLOOD | LOW-DOSE IL-2 | Lymph Nodes - pathology | Dendritic Cells - immunology | Humans | Middle Aged | Male | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Interleukin-2 - administration & dosage | Immunotherapy | Adult | Female | Hemocyanins - immunology | Injections, Intradermal | Drug Administration Routes | Forkhead Transcription Factors - biosynthesis | HLA-A2 Antigen - immunology | Antigens, Neoplasm - immunology | Cancer Vaccines - administration & dosage | Neoplasm Recurrence, Local | Treatment Outcome | Lymph Nodes - immunology | Cancer Vaccines - immunology | B-Lymphocytes - immunology | Melanoma - immunology | T-Lymphocytes - immunology | Aged | Melanoma - therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody
by Onizuka, Shozaburo and Tawara, Isao and Shimizu, Jun and Sakaguchi, Shimon and Fujita, Teizo and Nakayama, Eiichi
Cancer Research, ISSN 0008-5472, 07/1999, Volume 59, Issue 13, pp. 3128 - 3133
Immune regulation has been shown to be involved in the progressive growth of some murine tumors. In this study, we demonstrated that a single in vivo... 
UNIQUE ANTIGEN | CELLS | CD4 | ONCOLOGY | MICE | LEUKEMIA | IL-2 RECEPTOR | AUTOIMMUNE-DISEASE | RL-MALE-1 | CYTOTOXIC T-LYMPHOCYTES | SELF-TOLERANCE | Leukemia, Radiation-Induced - therapy | Mice, Inbred A | Fibrosarcoma - therapy | Antibodies, Monoclonal - therapeutic use | Fibrosarcoma - immunology | Male | Multiple Myeloma - immunology | Fibrosarcoma - chemically induced | Lymph Nodes - immunology | Lymphocyte Depletion | Receptors, Interleukin-2 - immunology | CD4-Positive T-Lymphocytes - immunology | Leukemia, Experimental - immunology | Multiple Myeloma - therapy | Animals | Flow Cytometry | Leukemia, Experimental - therapy | Lymphocytes - immunology | Mice, Nude | Leukemia, Radiation-Induced - immunology | Female | Mice | Mice, Inbred BALB C | CD8-Positive T-Lymphocytes - immunology | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Induction of tolerance to factor VIII by transient co‐administration with rapamycin
by MOGHIMI, B and SACK, B. K and NAYAK, S and MARKUSIC, D. M and MAH, C. S and HERZOG, R. W
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 08/2011, Volume 9, Issue 8, pp. 1524 - 1533
See also Miao CH. Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors. This issue, pp 1521–3.DOI:. Summary. ... 
hemophilia | inhibitor | factor VIII | T helper cell | tolerance | rapamycin | Tolerance | Inhibitor | Rapamycin | Factor VIII | Hemophilia | PREVENTION | ANTIGEN-SPECIFIC EFFECTOR | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | IMMUNE-RESPONSES | HEMOPHILIA-A MICE | FACTOR-IX | REGULATORY T-CELLS | PERIPHERAL VASCULAR DISEASE | GENE-THERAPY | INHIBITOR DEVELOPMENT | HEME OXYGENASE-1 | HEMATOLOGY | Factor VIII - immunology | Humans | Transforming Growth Factor beta1 - metabolism | Male | Adoptive Transfer | CD4-Positive T-Lymphocytes - immunology | Time Factors | Forkhead Transcription Factors - metabolism | Coagulants - administration & dosage | Interleukin-6 - metabolism | Immunosuppressive Agents - administration & dosage | Disease Models, Animal | Immune Tolerance - drug effects | Interleukin-2 - metabolism | Drug Administration Schedule | Hemophilia A - immunology | Interleukin-4 - metabolism | Mice, Inbred C57BL | Cells, Cultured | CTLA-4 Antigen - metabolism | Hemophilia A - blood | Recombinant Proteins - administration & dosage | Sirolimus - administration & dosage | Animals | CD4-Positive T-Lymphocytes - transplantation | Interleukin-2 Receptor alpha Subunit - metabolism | Factor VIII - administration & dosage | Antibodies - blood | Mice | Mice, Inbred BALB C | Coagulants - immunology | Hemophilia A - drug therapy | CD4-Positive T-Lymphocytes - drug effects | Blood coagulation factor VIII | T cells | Transforming growth factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti–PD-1 in melanoma
by Cheung, Laurene S and Fu, Juan and Kumar, Pankaj and Kumar, Amit and Urbanowski, Michael E and Ihms, Elizabeth A and Parveen, Sadiya and Bullen, C.Korin and Patrick, Garrett J and Harrison, Robert and Murphy, John R and Pardoll, Drew M and Bishai, William R
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 02/2019, Volume 116, Issue 8, pp. 3100 - 3105
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells and has been... 
Cancer immunotherapy | Fusion toxin | Tregs | INTERLEUKIN-2 | DENILEUKIN DIFTITOX | SAFETY | MULTIDISCIPLINARY SCIENCES | NK-CELLS | COMBINATION | cancer immunotherapy | fusion toxin | REGULATORY T-CELLS | FRAGMENT | DABIL-2 | PHASE-I | BINDING | Diphtheria Toxin - administration & dosage | Human Umbilical Vein Endothelial Cells - drug effects | Humans | Melanoma, Experimental - drug therapy | Melanoma, Experimental - pathology | Recombinant Fusion Proteins - chemistry | Corynebacterium diphtheriae - chemistry | Corynebacterium diphtheriae - pathogenicity | Interleukin-2 Receptor alpha Subunit - drug effects | Receptors, Interleukin-2 - immunology | Receptors, Interleukin-2 - genetics | Antibodies - administration & dosage | T-Lymphocytes, Regulatory - drug effects | Immunotoxins - administration & dosage | Melanoma, Experimental - genetics | Melanoma, Experimental - immunology | Interleukin-2 - administration & dosage | Amino Acid Substitution - genetics | Interleukin-2 - chemistry | Cell Proliferation - drug effects | Diphtheria Toxin - chemistry | Programmed Cell Death 1 Receptor - genetics | Immunosuppressive Agents - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Cell culture | PD-1 protein | Toxicity | Antibodies | Lymphocytes T | Agglomeration | Anticancer properties | Amino acid substitution | Proteins | Interleukin 2 | Lymphocytes | CD25 antigen | Inhibition | Fusion protein | Interleukin 2 receptors | Immunoregulation | Melanoma | Diphtheria | Lymphoma | Biological activity | Endothelial cells | Immunogenicity | Cell death | Production methods | Antitumor activity | Umbilical vein | T-cell lymphoma | Cancer | Tumors | Apoptosis | Index Medicus | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Activation of CD25+CD4+ Regulatory T Cells by Oral Antigen Administration
by Zhang, Xingmin and Izikson, Leonid and Liu, Liming and Weiner, Howard L
The Journal of Immunology, ISSN 0022-1767, 10/2001, Volume 167, Issue 8, pp. 4245 - 4253
CD25(+)CD4(+) T cells are naturally occurring regulatory T cells that are anergic and have suppressive properties. Although they can be isolated from the... 
INTESTINAL INFLAMMATION | ENCEPHALOMYELITIS | GROWTH-FACTOR-BETA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | IMMUNE-RESPONSES | EFFECTOR FUNCTION | IMMUNOLOGICAL SELF-TOLERANCE | MICE | INDUCTION | IMMUNOLOGY | AUTOIMMUNE-DISEASE | T-Lymphocyte Subsets - immunology | Administration, Oral | Lymphocyte Activation | Mice, Transgenic | Antigens - administration & dosage | CD4-Positive T-Lymphocytes - immunology | CTLA-4 Antigen | Receptors, Interleukin-2 - isolation & purification | Antigens, Differentiation - biosynthesis | Animals | Ovalbumin - administration & dosage | Abatacept | Immunoconjugates | Immune Tolerance - immunology | Autoimmune Diseases - therapy | Clonal Anergy - immunology | Mice | Mice, Inbred BALB C | Receptors, Antigen, T-Cell - genetics | Antigens, CD | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma
by Wei, Shuang and Kryczek, Ilona and Edwards, Robert P and Zou, Linhua and Szeliga, Wojciech and Banerjee, Mousumi and Cost, Marilyn and Cheng, Pui and Chang, Alfred and Redman, Bruce and Herberman, Ronald B and Zou, Weiping
Cancer Research, ISSN 0008-5472, 08/2007, Volume 67, Issue 15, pp. 7487 - 7494
Interleukin (IL)-2 is used in the immunotherapy of patients with certain cancer and HIV infection. IL-2 treatment reliably results in 16% to 20% objective... 
CONTROLLED-TRIAL | IMMUNITY | THERAPY | METASTATIC RENAL-CANCER | ONCOLOGY | IN-VIVO | PHASE-II | DOSE INTERLEUKIN-2 | RECOMBINANT INTERLEUKIN-2 | HIV-INFECTED PATIENTS | CUTTING EDGE | Cell Separation | Humans | Middle Aged | Ovarian Neoplasms - pathology | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | Cell Movement - drug effects | Antigen-Presenting Cells | Forkhead Transcription Factors - metabolism | Interleukin-2 - administration & dosage | Lymphocyte Activation - drug effects | Immunotherapy | Female | T-Lymphocytes - immunology | Cell Proliferation - drug effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Interleukin-35 administration counteracts established murine type 1 diabetes - possible involvement of regulatory T cells
by Singh, Kailash and Kadesjö, Erik and Lindroos, Julia and Hjort, Marcus and Lundberg, Marcus and Espes, Daniel and Carlsson, Per-Ola and Sandler, Stellan and Thorvaldson, Lina and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Transplantation och regenerativ medicin and Uppsala universitet and Institutionen för medicinska vetenskaper and Institutionen för medicinsk cellbiologi
Scientific Reports, ISSN 2045-2322, 07/2015, Volume 5, Issue 1, pp. 12633 - 12633
The anti-inflammatory cytokine IL-35 is produced by regulatory T (Treg) cells to suppress autoimmune and inflammatory responses. The role of IL-35 in type 1... 
B-CELLS | AUTOIMMUNE | NEUROPILIN-1 | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION FACTOR FOXP3 | IN-VIVO | HELPER-CELLS | INDUCED ARTHRITIS | TNF-ALPHA | IL-35 | EXPRESSION | Leukocytes, Mononuclear - metabolism | T-Lymphocytes, Regulatory - metabolism | Minor Histocompatibility Antigens | Humans | Diabetes Mellitus, Type 1 - metabolism | Interleukin-10 - blood | Male | Recombinant Proteins - biosynthesis | Interleukins - metabolism | T-Lymphocytes, Regulatory - immunology | Recombinant Proteins - isolation & purification | Interleukins - genetics | Diabetes Mellitus, Experimental - prevention & control | Flow Cytometry | Forkhead Transcription Factors - metabolism | T-Lymphocytes, Helper-Inducer - immunology | T-Lymphocytes, Helper-Inducer - cytology | T-Lymphocytes, Regulatory - cytology | Diabetes Mellitus, Experimental - chemically induced | Receptors, Cytokine - metabolism | Thymus Gland - metabolism | Disease Models, Animal | Interleukin-2 - metabolism | Hyperglycemia - prevention & control | T-Lymphocytes, Helper-Inducer - metabolism | Cytokines - metabolism | Enzyme-Linked Immunosorbent Assay | Interleukins - blood | Diabetes Mellitus, Type 1 - pathology | Transforming Growth Factor beta - blood | Recombinant Proteins - administration & dosage | Diabetes Mellitus, Experimental - immunology | Phenotype | Animals | Interleukins - administration & dosage | Spleen - metabolism | Diabetes Mellitus, Type 1 - blood | Leukocytes, Mononuclear - cytology | Mice, Inbred NOD | Mice | Streptozocin - toxicity | Immunoregulation | Streptozocin | Diabetes mellitus | T cell receptors | Lymphocytes T | Inflammation | Interleukin 17 | Hyperglycemia | Interleukin 2 | Rodents | Interleukin 10 | Interferon | Diabetes | Autoimmune diseases | Index Medicus | Biological Sciences | Naturvetenskap | Natural Sciences | Cellbiologi | Biologiska vetenskaper | Cell Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights